Market Reports

PCI expands analytical laboratories at Tredegar site

PCI expands analytical laboratories at Tredegar site

Pharmaceutical outsourcing services provider PCI announces laboratory expansion at contained manufacturing centre
Standing strong

Standing strong

As regulatory pressure keeps rising, affecting every aspect of the drug manufacturing process, quality is an ongoing quest for pharma companies. Kevin Robinson spoke to Christina Rettig, Head of Communications at SCHOTT AG to find out more
Addressing glass particulates in injectable drug formulations

Addressing glass particulates in injectable drug formulations

Glass particles are a frequent contaminant risk when producing injectable drugs on high speed filling lines. Glassmaker Corning has studied the root causes and engineered a new glass product for use on existing equipment that significantly reduces that risk
Serialisation: one year and counting

Serialisation: one year and counting

The Falsified Medicines Directive (FMD) introduces pan-European measures to prevent counterfeit medicines from entering the supply chain
A modern take on sterility assurance

A modern take on sterility assurance

Pharmaceutical manufacturers are increasingly looking for strategies to address containment risks. Christian Dunne of ChargePoint Technology sheds light on the benefit of split butterfly valve technology (SBV) in the aseptic processing of sterile active APIs and the final product
A look back at 2017 healthcare transactions

A look back at 2017 healthcare transactions

Last year, 2017, saw 2011 deals complete, with Q2 showing the strongest performance with 29.4%, followed by Q1 with 27.6%, Q3 with 24.1% and Q4 with 18.9%
Weathering the Brexit storm

Weathering the Brexit storm

The effective use of technology could facilitate regulatory compliance for pharmaceutical companies
Performance validation: HPAPI containment testing in a risk-based era

Performance validation: HPAPI containment testing in a risk-based era

Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance
Gene transfer therapy approved for the treatment of ALL: part I

Gene transfer therapy approved for the treatment of ALL: part I

In August 2017, Novartis received FDA approval for its chimeric antigen receptor T (CAR-T) cell therapy, Kymriah, for the treatment of children and young adults with B-cell acute lymphoblastic leukaemia (ALL)
The race to be first: drug delivery systems for biosimilars

The race to be first: drug delivery systems for biosimilars

For biosimilar manufacturers, the market potential is significant, especially for those that are first to market
Improving cold chain performance and reliability

Improving cold chain performance and reliability

The need to mitigate risks within global pharmaceutical supply chain logistics is driving innovation within the temperature-controlled packaging sector

Trending Articles

  1. A rules-based approach to labelling and artwork management: Part I Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative, says Graham Francis, Channel Marketing Manager, Kallik
  2. A microfluidic approach to production of alginate beads for cell encapsulation Gurinder Vinner, Material Scientist at Dolomite Microfluidics, discusses the benefits of continuous microfluidic production for the encapsulation of mammalian cells with no loss of viability
  3. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  4. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  5. CMC strategies for the acceleration of commercial-ready ADC manufacturing The potential for antibody-drug conjugate (ADC) programmes to accelerate from early to late stage clinical development highlights the need to establish commercial launch-ready manufacturing early and efficiently, reports Courtney Morgret, Senior Scientist, Manufacturing Sciences, AbbVie

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all